Antitumour Anthracyclines: Progress and Perspectives

Autor(es)

Martins-Teixeira, Maristela B. ^[1] ; Carvalho, Ivone ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ave Cafe S-N, Ribeirao Preto 14040903 - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CHEMMEDCHEM; v. 15, n. 11 MAY 2020.
• Citações Web of Science: 0

Resumo

Anthracyclines are ranked among the most effective chemotherapeutics against cancer. They are glycoside drugs comprising the amino sugar daunosamine linked to a hydroxy anthraquinone aglycone, and act by DNA intercalation, oxidative stress generation and topoisomerase II poisoning. Regardless of their therapeutic value, multidrug resistance and severe cardiotoxicity are important limitations of anthracycline treatment that have prompted the discovery of novel analogues. This review covers the most clinically relevant anthracyclines and their development over decades, since the first discovered natural prototypes to recent semisynthetic and synthetic derivatives. These include registered drugs, drug candidates undergoing clinical trials, and compounds under pre-clinical investigation. The impact of the structural modifications on antitumour activity, toxicity and resistance profile is addressed. (AU)

• Processo FAPESP: 15/10837-0 - Síntese de novos derivados de antraciclina contendo azido glicosídeos
• Beneficiário: Maristela Braga Martins Teixeira
• Modalidade de apoio: Bolsas no Brasil - Doutorado